Search clinical trials for: Fluticasone Furoate/GW642444 Inhalation Powder

Total 330 results

GlaxoSmithKline

Completed

A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma

Asthma

Japan
GlaxoSmithKline

Completed

Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Asthma

United States, Germany, Japan, Romania, Russian Federation, Poland
GlaxoSmithKline

Completed

Long-term Safety Study for GSK573719/GW642444 in Japanese (DB2115362)

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Asthma

United States, Germany, Japan, Romania, Ukraine, Poland
GlaxoSmithKline

Completed

Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Romania, Russian Federation, Ukraine, Argentina, Poland, Czechia
GlaxoSmithKline

Completed

A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Russian Federation, Chile, Poland, Mexico, Estonia, Korea, Republic of, Philippines
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Germany, Estonia, Chile, Netherlands, Peru, South Africa, Sweden, Mexico, United Kingdom, Italy, Philippines, Canada
GlaxoSmithKline

Completed

A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Australia, Argentina, Germany, Spain, South Africa, Mexico, Peru, Netherlands, Canada, United Kingdom, Denmark, Chile, Italy, Sweden
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy Subjects

Asthma

Australia
GlaxoSmithKline

Withdrawn

A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise

Asthma
GlaxoSmithKline

Completed

Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis

Asthma

United States, Germany, Poland
GlaxoSmithKline

Completed

Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler

Asthma

United Kingdom
GlaxoSmithKline

Completed

Asthma Exacerbation Study

Asthma

United States, Argentina, Germany, Japan, Poland, Romania, Russian Federation, Mexico, Ukraine, Australia, Philippines
GlaxoSmithKline

Completed

Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study

Asthma

United States, Germany, Thailand, Ukraine
Organon and Co

Terminated

Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(TERMINATED)

Asthma
GlaxoSmithKline

Completed

HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents

Asthma

United States, Argentina, Korea, Republic of, Netherlands, Philippines, Chile
GlaxoSmithKline

Completed

Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response

Asthma

Sweden, Australia, New Zealand
Neutec Ar-Ge San ve Tic A.Ş

Completed

Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment

COPD

Turkey
University of Saskatchewan

Completed

Effect of Vilanterol on Methacholine Challenge Results

Asthma

Canada
GlaxoSmithKline

Completed

Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.

Asthma

Korea, Republic of, China, Philippines
AlgiPharma AS
Imperial College London; Cystic Fibrosis Foundation; University Hospital of Cologne and other collaborators

Withdrawn

A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis (SMR3372)

Cystic Fibrosis

Germany
GlaxoSmithKline

Completed

A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects

Asthma

Japan
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

Asthma | Chronic Obstructive Pulmonary Disease COPD

United States
Mannkind Corporation

Completed

A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males

Diabetes Mellitus, Type 2 | Healthy Males

Netherlands
GlaxoSmithKline

Completed

Fluticasone Nasal Spray Patient Preference Study

Rhinitis, Allergic, Perennial

United States
GlaxoSmithKline

Completed

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma

Asthma

United States, Argentina, Germany, Korea, Republic of, Romania, Russian Federation, Spain, Netherlands, Mexico, Brazil, Chile, Czechia
GlaxoSmithKline

Completed

A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD

Pulmonary Disease, Chronic Obstructive

Argentina, France, Germany, Russian Federation, Ukraine, Italy, Norway
GlaxoSmithKline

Completed

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.

Asthma

United States, Argentina, Germany, Romania, Russian Federation, Ukraine, Chile, Sweden, Mexico, Netherlands, Poland
GlaxoSmithKline

Completed

A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.

Asthma

Germany, Romania, Bulgaria, Chile, Russian Federation, South Africa, Estonia, Italy, Mexico, Greece, Hungary, Croatia, Brazil
Mannkind Corporation

Completed

Comparison of 30 Units of TI (Technosphere® Insulin) Prepared With Insulin From Two Different Suppliers

Healthy Volunteers

United States
GlaxoSmithKline

Completed

Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response

Asthma

United Kingdom, Germany, New Zealand
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma (ANASSA-PD)

Asthma

Greece
GlaxoSmithKline

Completed

Corrected QT (QTc) Study With Flucticasone Furoate and GW642444

Asthma

United Kingdom
Mahidol University

Recruiting

As Needed Versus Regular Intranasal Corticosteroid in Children With Perennial Allergic Rhinitis

Perennial Allergic Rhinitis | Child, Only

Thailand
Mannkind Corporation

Completed

A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Netherlands
GlaxoSmithKline
Adelphi Real World

Completed

A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures

Rhinitis, Allergic, Perennial
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade

Bioequivalence

Greece
Savara Inc.

Completed

AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis

Cystic Fibrosis | MRSA

United States, Canada
Mannkind Corporation

No longer available

Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

Type 1 Diabetes | Type 2 Diabetes

United States
GlaxoSmithKline

Completed

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Japan, Poland, Romania, Russian Federation, Spain, Ukraine, Germany, Taiwan, Bulgaria, Hungary, France, Philippines, South Africa, Thailand, Israel, Korea, Republic of, Australia, Mexico, Slovakia, United... and more
GlaxoSmithKline

Completed

Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study

Asthma

United States
Savara Inc.
Cystic Fibrosis Foundation; Synteract, Inc.

Completed

Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

Cystic Fibrosis

United States
Morten Hostrup, PhD

Recruiting

Role of Lung Function for Exercise Capacity in Well-trained Individuals

Exercise Performance

Denmark
GlaxoSmithKline

Completed

Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects

Asthma

United Kingdom, Germany
GlaxoSmithKline

Completed

A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Romania, Russian Federation, United States, Ukraine
Organon and Co

Completed

Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhinitis Patients (I94-001)

Rhinitis, Allergic, Seasonal
Morten Hostrup, PhD

Recruiting

U-LABA/ICS Effects on Exercise Performance, Vilanterol

Exercise Performance

Denmark
GlaxoSmithKline

Completed

Bioequivalence Study to Compare Fluticasone Furoate (FF) 1-strip Inhaler With FF 2-strip Inhaler and With FF/Vilanterol Combination

Asthma

Germany

3

Subscribe